# Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of <i>KRAS</i> -Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study

*PRI Rank #16 · Topics and Trends in Most Cited Microtubule and mitosis dynamics Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/microtubule-and-mitosis-dynamics/2026/rank-16*

| Field | Value |
| --- | --- |
| Rank | #16 |
| 18m citations | 28 |
| Journal | Clinical Cancer Research |
| Year | 2024 |
| DOI | 10.1158/1078-0432.ccr-23-3053 |
| Corresponding authors | Daniel H Ahn, Afsaneh Barzi, Maya Ridinger |
| Institution | Mayo Clinic, United States |

**Ranking page:** [Topics and Trends in Most Cited Microtubule and mitosis dynamics Papers, Class of 2026](https://pri.pepkio.com/top-papers/microtubule-and-mitosis-dynamics/2026)

**Paper link:** [10.1158/1078-0432.ccr-23-3053](https://doi.org/10.1158/1078-0432.ccr-23-3053)

## Topics

onvansertib · PLK1 · KRAS-mutant colorectal cancer · FOLFIRI · bevacizumab · second-line treatment · metastatic colorectal cancer · phase Ib clinical trial · irinotecan · circulating tumor DNA (ctDNA) · KRAS wild-type isogenic cells · xenograft model · neutropenia · recommended phase II dose · partial response · ctDNA dynamics · oxaliplatin exposure · antitumor activity

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Microtubule and mitosis dynamics Papers, Class of 2026. https://pri.pepkio.com/top-papers/microtubule-and-mitosis-dynamics/2026. Accessed 2026-07-23.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```